Literature DB >> 9479935

Retinal arterial macroaneurysm: a case report.

A S Gurwood1, C R Nicholson.   

Abstract

BACKGROUND: Retinal arterial macroaneurysms are an acquired retinal vascular abnormality. These isolated dilatations of the major retinal arterial branches are found within the posterior pole and are associated with systemic hypertension, arteriosclerosis, retinal emboli and cardiovascular disease.
RESULTS: Although many patients are asymptomatic, vision loss is the most commonly manifested symptom. Vision loss may occur as a result of hemorrhage (subretinal, intraretinal, preretinal or vitreous) or macular edema with associated lipoprotein exudation. Most lesions spontaneously involute without causing any visual consequence. If central vision is reduced or threatened, laser photocoagulation may be applied directly to the macroaneurysm itself or to affected retinal capillary beds. While retinal arterial macroaneurysms frequently manifest as isolated phenomena with few symptoms (loss of visual acuity if bleeding or exudation encroaches on the macula), their differential diagnosis includes retinal and systemic diseases that require thorough investigation.
CONCLUSION: Optometrists should be familiar with the signs and symptoms of retinal arterial macroaneurysms, their differential diagnosis, workup, and management.

Entities:  

Mesh:

Year:  1998        PMID: 9479935

Source DB:  PubMed          Journal:  J Am Optom Assoc        ISSN: 0003-0244


  3 in total

Review 1.  Ruptured retinal arterial macroaneurysm: diagnosis and management.

Authors:  Ashley M Speilburg; Stephanie A Klemencic
Journal:  J Optom       Date:  2013-09-26

2.  Need of preventive photocoagulation for retinal arterial macroaneurysm with retinal hemorrhage.

Authors:  Daisuke Nagasato; Takuji Iwawaki; Hitoshi Tabuchi
Journal:  Clin Case Rep       Date:  2022-04-05

3.  Outcomes of combined treatments in patients with retinal arterial macroaneurysm.

Authors:  Chenghu Wang; Guofan Cao; Xiangzhong Xu; Jian Wang; Shu Zhang
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.